Álvaro Martín-Montes

Dr. Álvaro Martín-Montes

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RERUBEN MARTIN ESCOLANO
RUBEN MARTIN ESCOLANO
MVMoreno De Viguri
Moreno De Viguri
MSMery Santivañez-Veliz
Mery Santivañez-Veliz
ÁMÁlvaro Martín-Montes
Álvaro Martín-Montes
EMEncarnacion Medina-Carmona
Encarnacion Medina-Carmona
MSManuel Sánchez-Moreno
Manuel Sánchez-Moreno

6 December 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MVMoreno De Viguri
Moreno De Viguri
CJCarmen Jiménez-Montes
Carmen Jiménez-Montes
RERUBEN MARTIN ESCOLANO
RUBEN MARTIN ESCOLANO
MSMery Santivañez-Veliz
Mery Santivañez-Veliz
ÁMÁlvaro Martín-Montes
Álvaro Martín-Montes
SSSilvia Pérez Silanes
Silvia Pérez Silanes

1 June 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
ÁMÁlvaro Martín-Montes
Álvaro Martín-Montes
Plano DanielPlano Daniel
Plano Daniel
RERUBEN MARTIN ESCOLANO
RUBEN MARTIN ESCOLANO
VAVeronica Alcolea
Veronica Alcolea
MDMarta Díaz
Marta Díaz
MSManuel Sánchez-Moreno
Manuel Sánchez-Moreno
The in vitro leishmanicidal activities of a series of 48 recently synthesized selenium derivatives against Leishmania infantum and Leishmania braziliensis parasites were tested using promastigotes and intracellular amastigote forms. The cytotoxicity of the tested compounds for J774.2 macrophage cells was also measured in order to establish their selectivity. Six of the tested compounds (compounds 8, 10, 11, 15, 45, and 48) showed selectivity indexes higher than those of the reference drug, meglumine antimonate (Glucantime), for both Leishmania species; in the case of L. braziliensis , compound 20 was also remarkably selective. Moreover, data on infection rates and amastigote numbers per macrophage showed that compounds 8, 10, 11, 15, 45, and 48 were the most active against both Leishmania species studied. The observed changes in the excretion product profile of parasites treated with these six compounds were also consistent with substantial cytoplasmic alterations. On the other hand, the most active compounds were potent inhibitors of Fe superoxide dismutase (Fe-SOD) in the two parasite species considered, whereas their impact on human CuZn-SOD was low. The high activity, low toxicity, stability, low cost of the starting materials, and straightforward synthesis make these compounds appropriate molecules for the development of affordable antileishmanicidal agents.

1 February 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RERUBEN MARTIN ESCOLANO
RUBEN MARTIN ESCOLANO
DMDaniel Molina-Carreño
Daniel Molina-Carreño
EPEstefanía Delgado Pinar
Estefanía Delgado Pinar
ÁMÁlvaro Martín-Montes
Álvaro Martín-Montes
MCM. Paz Clares
M. Paz Clares
CMClotilde Marín
Clotilde Marín

4 September 2018 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
RERUBEN MARTIN ESCOLANO
RUBEN MARTIN ESCOLANO
BABenjamín Aguilera‐Venegas
Benjamín Aguilera‐Venegas
CMClotilde Marín
Clotilde Marín
ÁMÁlvaro Martín-Montes
Álvaro Martín-Montes
JMJavier Martín‐Escolano
Javier Martín‐Escolano
MSManuel Sánchez‐Moreno
Manuel Sánchez‐Moreno

9 August 2017 in Parasitology
Verified
Journal Article
Closed access
PDF file
ÁMÁlvaro Martín-Montes
Álvaro Martín-Montes
MSMery Santivañez-Veliz
Mery Santivañez-Veliz
EMElsa Moreno-Viguri
Elsa Moreno-Viguri
RERUBEN MARTIN ESCOLANO
RUBEN MARTIN ESCOLANO
CJCarmen Jiménez-Montes
Carmen Jiménez-Montes
SSSilvia Pérez Silanes
Silvia Pérez Silanes
SUMMARY: Leishmaniasis is one of the world's most neglected diseases, and it has a worldwide prevalence of 12 million. There are no effective human vaccines for its prevention, and treatment is hampered by outdated drugs. Therefore, research aiming at the development of new therapeutic tools to fight leishmaniasis remains a crucial goal today. With this purpose in mind, we present 20 arylaminoketone derivatives with a very interesting in vitro and in vivo efficacy against Trypanosoma cruzi that have now been studied against promastigote and amastigote forms of Leishmania infantum, Leishmania donovani and Leishmania braziliensis strains. Six out of the 20 Mannich base-type derivatives showed Selectivity Index between 39 and 2337 times higher in the amastigote form than the reference drug glucantime. These six derivatives affected the parasite infectivity rates; the result was lower parasite infectivity rates than glucantime tested at an IC25 dose. In addition, these derivatives were substantially more active against the three Leishmania species tested than glucantime. The mechanism of action of these compounds has been studied, showing a greater alteration in glucose catabolism and leading to greater levels of iron superoxide dismutase inhibition. These molecules could be potential candidates for leishmaniasis chemotherapy.